DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease.
In this review, study researchers explained how procedural sequence learning and event file binding are 2 cognitive mechanisms underlying habitual behavior in Gilles de la Tourette syndrome.
The review authors sought to elucidate the neurological harms of methamphetamine, which are well-documented but poorly understood.
This phase 2, double-blind trial of solriamfetol evaluated the dose-dependent effects on sleep latency in patients with Parkinson disease.
Study researchers assessed the role of cognitive control processes in tic severity reduction, as well as treatment response to behavioral therapy in youth with Tourette disorder.
The study researchers reported on a self-assembled hydrogel to deliver the drug 4-dihydroxyphenylalanine (L-DOPA) for Parkinson disease.
Because sargramostim therapeutic use has been offset by dose-dependent adverse events, the researchers performed a reduced drug dose regimen to evaluate safety and to discover novel disease-linked biomarkers during sargramostim treatments for 1 year.
The researchers’ goal studied whether exposure to particulate matters, nitrogen dioxide, ozone, sulfur dioxide, or carbon monoxide raises the risk of Parkinson disease.
Older adults with cerebral palsy and musculoskeletal disorders have lower use of PT services compared with their peers without CP.
A team of investigators observed people with essential tremor and their relatives to determine the relationship between essential tremor, Parkinson disease, and dystonia.